 |
Mortality
in SS disease is increased in early life (1;2), with greatest mortality experienced
between the ages of 6 months and 3 years (3;4;5), and the possibility of missing
mortality, especially in early childhood, must be considered (6). Late-entry will impact
on survival estimates if mortality rates for patients in and out of a study are different.
Techniques to compensate for late-entry are applied during data analysis.References
(1) Rogers DW, Clarke JM, Cupidore L, Ramlal AM, Sparke BR,
Serjeant GR. Early deaths in Jamaican children with sickle cell disease. Br Med J 1978;
1(6126):1515-1516.
(2) Lee A, Thomas P, Cupidore L, Serjeant B, Serjeant G. Improved
survival in homozygous sickle cell disease: lessons from a cohort study. BMJ 1995;
311(7020):1600-1602.
(3) Serjeant GR, Serjeant BE. Management of sickle cell disease;
lessons from the Jamaican Cohort Study. Blood Rev 1993; 7(3):137-145.
(4) Gill FM, Sleeper LA, Weiner SJ, Brown AK, Bellevue R, Grover R
et al. Clinical events in the first decade in a cohort of infants with sickle cell
disease. Cooperative Study of Sickle Cell Disease. Blood 1995; 86(2):776-783.
(5) Leikin SL, Gallagher D, Kinney TR, Sloane D, Klug P, Rida W.
Mortality in children and adolescents with sickle cell disease. Cooperative Study of
Sickle Cell Disease. Pediatrics 1989; 84(3):500-508.
(6) Corey M. Survival estimates in cystic fibrosis: snapshots of a
moving target. Pediatric Pulmonology 1996; 21:149-150. |
